Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.

Haematologica - 1 Mar 2011

Nielsen Camilla, Birgens Henrik S, Nordestgaard Børge G, Kjaer Lasse, Bojesen Stig E

Abstract excerpt

JAK2 V617F is present in the majority of patients with myeloproliferative cancer; however, its prevalence and clinical significance in the general population is unknown. We screened for presence of the mutation in 10,507 participants from the Copenhagen City Heart Study with up to 17.6 years of f...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hematologic Neoplasms
Share to Janus Kinase 2
Share to Longitudinal Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Share to Population Surveillance

Share to Proportional Hazards Models

Share to Risk Factors

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 21160067
DOI: 10.3324/haematol.2010.033191
PMCID: PMC3046277

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21160067-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.PMID 21160067Read ↗

Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.Semantic proximity Read ↗

Prevalence of JAK 2 v617 Mutations in Malignant and Non-Malignant Tumors in the Eastern Province of the Kingdom of Saudi Arabia.Semantic proximity Read ↗

Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysis.Semantic proximity Read ↗

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.Semantic proximity Read ↗

JAK2 V617F: a single mutation in the myeloproliferative group of disorders.Semantic proximity Read ↗

[Somatic mutation of the V617F JAK2 gene in patients of the cardiovascular diseases].Semantic proximity Read ↗

[Somatic JAK2 gene mutation is an evolving risk factor in cardiovascular diseases].Semantic proximity Read ↗

The CHIP-clinic as the catalyst of preventive medicineSemantic proximity Read ↗

Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F.Semantic proximity Read ↗

Full spectrum of clonal haematopoiesis-driver mutations in chronic heart failure and their associations with mortality.Semantic proximity Read ↗

Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosisSemantic proximity Read ↗

Clonal Hematopoiesis and JAK2V617F Mutations in Patients With Cardiovascular DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.